ClinicalTrials.gg
RecruitingNCT07161544CELESTEUpdated Sep 30, 2026

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

A Phase 1/2 interventional study of AAVB-039 in Stargardt Disease, sponsored by AAVantgarde Bio Srl. Recruiting at 11 sites in 3 countries. Open to participants aged 8 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by AAVantgarde Bio Srl · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Sep 30, 2026First site in Norway2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
8 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.

Planned enrollment
9th of 26
75 · median 41
Started
2025
with 3 others
Phase 1/2
7 of 42
3 open now
Primary completion
2032-07
later than 22 of 24 live
Registered
36th of 42
by date
Lead sponsor
2 of 42
AAVantgarde Bio Srl

Among the 42 studies in Stargardt Disease with a site in United States, this one is the 9th largest by planned enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2025, is one of 7 in phase 1/2, reaches primary completion later than 22 of the 24 other live ones, and was the 36th registered.

Stargardt Disease

68 studies on the registry are indexed under Stargardt Disease; 27 are open to participants now.

Browse Stargardt Disease studies →

Open to participants now

16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Stargardt Disease studies recruiting now, 15 (63%) set no upper age limit and 7 (29%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 8 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Stargardt Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.

03

Conditions studied

  • Stargardt Disease

Browse trials for

Keywords

  • Stargardt Disease
  • Biallelic Mutation
  • Gene Mutation
  • ABCA4
04

Who can participate

Ages eligible
8 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Molecular diagnosis of Stargardt disease due to ABCA4 mutation
  • Willingness to adhere to protocol per

Exclusion criteria

Exclusion Criteria:

  • Unwillingness to meet the requirements of the study
  • Participation in a clinical study with another Investigation Medicinal Product
  • Previous participation in another gene or cell therapy trial
  • Any condition that would preclude subretinal surgery
  • Complicating ocular and/or systemic diseases
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    AAVB-039 dose level 1 (low dose)

    Biological: AAVB-039

  • Experimental
    Cohort 2

    AAVB-039 dose level 2 (mid dose)

    Biological: AAVB-039

  • Experimental
    Cohort 3

    AAVB-039 dose level 3 (high dose)

    Biological: AAVB-039

  • Experimental
    Cohorts 4-5

    AAVB-039 dose level 1, 2 or 3

    Biological: AAVB-039

Interventions

  • BiologicalAAVB-039

    Single subretinal administration

06

What researchers measure

Primary outcomes

  1. To measure the number and severity of treatment related adverse events following treatment with AAVB-039

    Time frame: 0-60 months

Secondary outcomes

  1. Change in the area of atrophy (assessed via short wavelength fundus autofluorescence (SW-FAF), following treatment with AAVB-039

    Time frame: 0-60 months

  2. Change in ellipsoid zone (EZ) loss following treatment with AAVB-039

    Time frame: 0-60 months

  3. Change in macular sensitivity assessed via microperimetry following treatment with AAVB-039

    Time frame: 0-60 months

  4. Change in visual acuity following treatment with AAVB-039

    Time frame: 0-60 months

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jul 2032, 82 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Sep 8, 2025
StartActual
Sep 29, 2025
Primary completionEst.
Jul 2032
CompletionEst.
Jul 2032
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added — first site in Norway
Show 2 added (1 United States, 1 Norway)
  • Children's Hospital Los Angeles · Los Angeles, United States
  • Oslo University Hospital · Oslo, Norway
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    2 sites added — first site in Norway
    Show 2 added (1 United States, 1 Norway)
    • Children's Hospital Los Angeles · Los Angeles, United States
    • Oslo University Hospital · Oslo, Norway
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07161544
Lead sponsor
AAVantgarde Bio Srl
Collaborators
AAVantgarde Bio UK Ltd
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Sep 29, 2025
Primary completion
Jul 2032 (estimated)
Completion
Jul 2032 (estimated)
Last update
Sep 30, 2026

Study contacts

AAVantgarde Clinical Operations Lead
Contact
clinicaltrials@aavantgarde.com
+448000465680

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion